Brasília – The federal government has allocated R$2.3 billion to acquire and distribute 385 doses of Zolgensma, a gene therapy indicated for spinal muscular atrophy (SMA), through Brazil’s Unified Health System (SUS). Known in the country as the world’s most expensive medicine, each dose is priced at about R$6.2 million—below its global market average of R$7 million.

The agreement between the Ministry of Health and Novartis Biociências S.A. runs until 2030 and introduces a results-based payment model: the government will release funds as patients show clinical improvement. The treatment, approved by Anvisa in 2020, is indicated for babies under six months diagnosed with type I SMA, a severe and progressive neuromuscular disease.

Source: Metrópoles

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com